• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens.采用减低剂量预处理方案的异基因造血细胞移植的成本。
Oncologist. 2014 Jun;19(6):639-44. doi: 10.1634/theoncologist.2013-0406. Epub 2014 May 5.
2
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
3
Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.估算异基因造血细胞移植患者的终身医疗费用负担。
Transplant Cell Ther. 2023 Oct;29(10):637.e1-637.e9. doi: 10.1016/j.jtct.2023.06.013. Epub 2023 Jun 24.
4
Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.在住院和门诊环境中进行的低强度预处理异基因造血细胞移植的结果。
Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833. doi: 10.1016/j.bbmt.2018.12.069. Epub 2018 Dec 18.
5
Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.在降低强度的预处理方案中使用抗胸腺细胞球蛋白可实现无长期慢性移植物抗宿主病的高无病生存率。
Biol Blood Marrow Transplant. 2014 Mar;20(3):370-4. doi: 10.1016/j.bbmt.2013.11.030. Epub 2013 Dec 4.
6
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.55岁以上患者的减低强度异基因移植:对于没有匹配的相关供者的患者,无关脐血是安全有效的。
Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9. doi: 10.1016/j.bbmt.2007.12.488.
7
Costs of second allogeneic hematopoietic cell transplantation.第二例同种异体造血细胞移植的费用。
Transplantation. 2013 Jul 15;96(1):108-15. doi: 10.1097/TP.0b013e318294caf1.
8
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.使用白消安、氟达拉滨和抗胸腺细胞球蛋白进行减低强度预处理用于缓解期急性髓系白血病患者接受无关或单倍体相合家庭供者造血细胞移植
Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25.
9
Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.供者年龄对异基因造血细胞移植后结局的影响。
Biol Blood Marrow Transplant. 2015 Jan;21(1):105-12. doi: 10.1016/j.bbmt.2014.09.021. Epub 2014 Sep 30.
10
Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.在开发早期评估临床策略:异基因外周血干细胞移植的成本分析
Bone Marrow Transplant. 1999 Sep;24(5):555-60. doi: 10.1038/sj.bmt.1701945.

引用本文的文献

1
A comparison of haploidentical versus HLA-identical sibling outpatient hematopoietic cell transplantation using reduced intensity conditioning in patients with acute leukemia.比较亲缘单倍体与 HLA 同型相匹配同胞供者在急性白血病患者中采用减低强度预处理方案的门诊造血细胞移植。
Front Immunol. 2024 Oct 4;15:1400610. doi: 10.3389/fimmu.2024.1400610. eCollection 2024.
2
Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective.接受异基因移植的血液系统恶性肿瘤患者的医疗保健费用:美国支付者视角。
Blood Adv. 2024 Mar 12;8(5):1200-1208. doi: 10.1182/bloodadvances.2023011033.
3
Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia.医疗保险受益人群中急性髓细胞白血病患者接受异基因造血细胞移植的利用趋势和未满足需求估计。
Transplant Cell Ther. 2022 Dec;28(12):852-858. doi: 10.1016/j.jtct.2022.09.015. Epub 2022 Sep 25.
4
Hematopoietic Stem Cells and Regeneration.造血干细胞与再生
Cold Spring Harb Perspect Biol. 2022 Aug 1;14(8):a040774. doi: 10.1101/cshperspect.a040774.
5
Selection of Suitable Alternative Donor in the Absence of Matched Sibling Donor: A Retrospective Single-Center Study to Compare between Haploidentical, 10/10 and 9/10 Unrelated Donor Transplantation.在缺乏匹配同胞供者的情况下选择合适的替代供者:一项回顾性单中心研究,比较单倍体相合、10/10和9/10非血缘供者移植
Int J Hematol Oncol Stem Cell Res. 2021 Jan 1;15(1):51-60. doi: 10.18502/ijhoscr.v15i1.5249.
6
Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis.长期造血干细胞移植幸存者的临床轨迹、医疗资源利用和成本:一种潜在类别分析。
J Cancer Surviv. 2020 Jun;14(3):294-304. doi: 10.1007/s11764-019-00842-1. Epub 2020 Jan 2.
7
Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid Leukemia.医疗保险受益的急性髓系白血病患者异基因移植后的报销、使用情况及1年生存率
JNCI Cancer Spectr. 2019 Aug 28;3(4):pkz048. doi: 10.1093/jncics/pkz048. eCollection 2019 Dec.
8
Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries.全球血液和骨髓移植网络(WBMT)观点:生物类似药在造血细胞移植中的作用:低收入和中低收入国家的当前机遇与挑战
Bone Marrow Transplant. 2020 Apr;55(4):698-707. doi: 10.1038/s41409-019-0658-2. Epub 2019 Sep 4.
9
Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.住院异体造血细胞移植受者的巨细胞病毒感染抢先治疗的临床和经济负担。
J Med Virol. 2020 Jan;92(1):86-95. doi: 10.1002/jmv.25574. Epub 2019 Sep 3.
10
Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.Rorc 抑制 ST2+调节性 T 细胞缓解肠道移植物抗宿主病的作用。
JCI Insight. 2019 Mar 7;4(5). doi: 10.1172/jci.insight.122014.

本文引用的文献

1
Costs of second allogeneic hematopoietic cell transplantation.第二例同种异体造血细胞移植的费用。
Transplantation. 2013 Jul 15;96(1):108-15. doi: 10.1097/TP.0b013e318294caf1.
2
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?对于老年造血干细胞移植受者来说,谁是更好的供者:年龄较大的同胞供者还是年轻、匹配的无关志愿者?
Blood. 2013 Mar 28;121(13):2567-73. doi: 10.1182/blood-2012-08-453860. Epub 2013 Jan 29.
3
Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database.美国自体和同种异体造血细胞移植的成本:一项使用大型全国私人索赔数据库的研究。
Bone Marrow Transplant. 2013 Feb;48(2):294-300. doi: 10.1038/bmt.2012.133. Epub 2012 Jul 9.
4
Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.克服造血干细胞移植中的年龄障碍:取得了进展,但仍任重道远。
JAMA. 2011 Nov 2;306(17):1918-20. doi: 10.1001/jama.2011.1612.
5
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.非清髓性预处理和异基因造血细胞移植治疗晚期血液系统恶性肿瘤的老年患者的长期结果。
JAMA. 2011 Nov 2;306(17):1874-83. doi: 10.1001/jama.2011.1558.
6
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.同种异体造血干细胞移植后,与移植中心的地理接近程度对结果的影响。
Biol Blood Marrow Transplant. 2012 May;18(5):708-15. doi: 10.1016/j.bbmt.2011.08.022. Epub 2011 Sep 8.
7
Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation.异基因造血干细胞移植后费用增加与主要并发症和再次移植有关。
Bone Marrow Transplant. 2012 May;47(5):706-15. doi: 10.1038/bmt.2011.162. Epub 2011 Aug 29.
8
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.非血缘供者移植后经减低强度预处理:使用部分 HLA 错配相关骨髓或无关双脐血移植物的平行 2 期试验结果。
Blood. 2011 Jul 14;118(2):282-8. doi: 10.1182/blood-2011-03-344853. Epub 2011 Apr 28.
9
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.年龄对缓解后接受低强度造血细胞移植的老年急性髓系白血病或骨髓增生异常综合征患者的预后的影响。
J Clin Oncol. 2010 Apr 10;28(11):1878-87. doi: 10.1200/JCO.2009.25.4821. Epub 2010 Mar 8.
10
Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated.收治造血细胞移植受者的医疗机构中的感染预防与控制。
Bone Marrow Transplant. 2009 Oct;44(8):495-507. doi: 10.1038/bmt.2009.261.

采用减低剂量预处理方案的异基因造血细胞移植的成本。

Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens.

作者信息

Khera Nandita, Emmert Amy, Storer Barry E, Sandmaier Brenda M, Alyea Edwin P, Lee Stephanie J

机构信息

Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Division of Hematology/Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA; Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

出版信息

Oncologist. 2014 Jun;19(6):639-44. doi: 10.1634/theoncologist.2013-0406. Epub 2014 May 5.

DOI:10.1634/theoncologist.2013-0406
PMID:24797822
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4041670/
Abstract

Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n = 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs.

摘要

减低强度预处理(RIC)方案使老年患者和合并症患者能够接受造血细胞移植(HCT)。我们分析了2008年1月至2010年12月在两家机构接受RIC-HCT的484例患者从预处理开始至HCT后100天以及311例患者长达2年的医疗费用。采用多元线性回归分析临床变量、中心效应和费用之间的关联。尽管在移植前性能评分方面存在差异,但各研究点的患者和移植特征具有可比性。前100天费用较低的显著预测因素包括淋巴瘤/骨髓瘤诊断以及使用人类白细胞抗原匹配的相关供者。II-IV级急性移植物抗宿主病(GVHD)与较高费用相关。在对临床变量进行调整后,两家机构的总体短期费用具有可比性(p = 0.43)。一个队列(n = 311)提供了HCT后100天至2年的后期费用;在此期间的中位费用为39,000美元,占前2年费用的39%。后期费用与任何移植前变量均无关联,但在广泛慢性GVHD和死亡情况下费用较高。在对临床特征进行调整后,尽管管理方法(住院与门诊预处理)和计费方法不同,但两家机构RIC移植的总体费用相似。使用无关/替代供者、移植淋巴瘤或骨髓瘤以外的疾病以及急性GVHD是早期费用较高的预测因素,而广泛慢性GVHD和死亡与后期费用较高相关。